Lazard Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.94M Buy
52,177
+8,052
+18% +$478K ﹤0.01% 976
2026
Q2
$2.66M Sell
44,125
-6,630
-13% -$368K ﹤0.01% 848
2026
Q1
$2.95M Sell
50,755
-27,908
-35% -$1.29M ﹤0.01% 742
2025
Q4
$3.53M Buy
+78,663
New +$3.3M 0.01% 665
2020
Q4
– Sell
-705
Closed -$7K – 2006
2020
Q3
$7K Buy
+705
New +$8.3K ﹤0.01% 1522

Other funds holding XENE

Lazard Asset Management's XENE Position: Q3 2026 in Review

Lazard Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 18% in Q3 2026, buying an estimated $478K and bringing the position to 52,177 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Lazard Asset Management first reported a position in XENE in Q3 2020 and has held it in 5 quarters since. The position peaked at $3.53M in Q4 2025. 288 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Lazard Asset Management held 52,177 shares of Xenon Pharmaceuticals worth $1.94M as of Q3 2026.
  • Lazard Asset Management bought 8,052 Xenon Pharmaceuticals shares in Q3 2026, an estimated $478K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #976 holding.
  • Lazard Asset Management first reported a position in Xenon Pharmaceuticals in Q3 2020 and has held it in 5 quarters since.
  • Lazard Asset Management's Xenon Pharmaceuticals position peaked at $3.53M in Q4 2025.
  • 288 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.